Class B G-protein-coupled receptors (GPCRs) are essential components in human physiological processes and serve as valuable drug targets for many diseases including diabetes, metabolic syndrome, osteoporosis, migraine, depression and anxiety [1] [2] [3] [4] . These receptors consist of an extracellular domain (ECD) and a transmembrane domain (TMD), both of which are required for binding to their endogenous peptide ligands and regulation of cell signal transduction 2, 5 . Previous studies suggested that tertiary interactions between the ECD and TMD play a critical role in regulating the receptor activity of class B GPCRs 6, 7 . Structures of the ECDs of several class B GPCRs have been solved 2 , and recently, the crystal structures of the TMDs of three class B GPCRs, the human GCGR 8, 9 , corticotrophin-releasing factor receptor 1 (CRF 1 R) 10 and glucagon-like peptide 1 receptor (GLP-1R) 11 , have been determined, providing insights into ligand recognition and selectivity of these physiologically important receptors. However, the structure of a full-length class B GPCR has remained elusive, thereby limiting our understanding of the molecular details accompanying peptide binding and signal transduction. In this study, we have solved the crystal structure of the full-length human GCGR in an inactive conformation in complex with a negative allosteric modulator (NAM) Table 1 ).
Overall structure of full-length GCGR
In the GCGR-NNC0640-mAb1 complex structure, GCGR exhibits an elongated conformation with the ECD sitting on top of the TMD (Fig. 1a) . The ECD comprises the common α -β -β -α fold as observed in the ECD structures of GCGR and other class B GPCRs 6, 12, 13 with C α r.m.s.d. of 1.3 Å compared to the same domain in the crystal structure of the GCGR ECD bound to mAb1 6 (PDB ID: 4ERS). Four asparagine residues, N46, N59, N74 and N78 within the ECD are glycosylated by N-acetyl-d-glucosamines (NAGs). The TMD in the full-length GCGR structure features the canonical seven-transmembrane helical bundle (helices I-VII), which shares a similar conformation compared to the previously solved crystal structures of the GCGR TMD 8, 9 with C α r.m.s.d. of 1.2 Å (PDB ID: 4L6R) and 0.8 Å (PDB ID: 5EE7). The antibody mAb1 interacts with the α A helix and loops L2, L4 and L5 of the GCGR ECD as previously reported 6 . Additionally, it makes close contact with the first extracellular loop (ECL1) of the receptor (Fig. 1b) , probably restricting conformational flexibility between the ECD and TMD. Our ligand-binding assay showed that mAb1 had little effect on the binding affinity of GCGR for NNC0640 (Extended Data Fig. 2a ).
The human glucagon receptor, GCGR, belongs to the class B G-protein-coupled receptor family and plays a key role in glucose homeostasis and the pathophysiology of type 2 diabetes. Here we report the 3.0 Å crystal structure of fulllength GCGR containing both the extracellular domain and transmembrane domain in an inactive conformation. The two domains are connected by a 12-residue segment termed the stalk, which adopts a β-strand conformation, instead of forming an α-helix as observed in the previously solved structure of the GCGR transmembrane domain. The first extracellular loop exhibits a β-hairpin conformation and interacts with the stalk to form a compact β-sheet structure. Hydrogen-deuterium exchange, disulfide crosslinking and molecular dynamics studies suggest that the stalk and the first extracellular loop have critical roles in modulating peptide ligand binding and receptor activation. These insights into the full-length GCGR structure deepen our understanding of the signalling mechanisms of class B G-protein-coupled receptors.
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GCGR binding mode of the NAM NNC0640
The NAM NNC0640 binds to GCGR on the external surface of the TMD in a similar binding site as previously reported for another GCGR NAM MK-0893 9 ( Fig. 2) . The tetrazole ring of NNC0640 inserts into a cleft between helices VI and VII forming hydrogen bonds with S350
6.41b and N404 7.61b (numbers in superscript refer to the modified Ballesteros-Weinstein numbering system for class B GPCRs 14, 15 ). The benzamide group of the ligand forms an additional polar interaction with S350 6.41b , while the urea carbonyl oxygen hydrogen-bonds with T353 6.44b . Unlike the dichlorophenylpyrazole group of MK-0893 that is oriented parallel to the membrane and makes no contact with the receptor, the cyclohexylphenyl moiety of NNC0640 forms hydrophobic contacts with helices VI and VII. Our mutagenesis studies show that the single-site mutants S350 6 Fig. 2b and Extended Data Table 2 ), which could be explained by the importance of the multiple hydrogen bonds between the ligand and these three residues.
Conformation of the stalk
The conformation of the stalk region (residues G125-K136) that connects the C terminus of the ECD and the extracellular tip of helix I either defines or responds to the relative orientation between the ECD and TMD. In the previously solved structure of the GCGR TMD (PDB ID: 4L6R), the stalk region forms a three-turn α -helical extension of helix I 8 . Surprisingly, the N-terminal portion of the stalk (G125-Q131) exhibits a different conformation in the inactive full-length GCGR structure by adopting a β -strand conformation that runs across the helical bundle flanked by ECL1 on one side and ECL2 and ECL3 on the other (Fig. 3a and Extended Data Fig. 3a) . With this unexpected difference in conformation of the stalk region, the relative orientation of the ECD and TMD observed in the inactive full-length GCGR crystal structure differs dramatically from what was previously predicted by modelling an active conformation of full-length GCGR in complex with its endogenous ligand glucagon 7, 8 (Extended Data Fig. 4a, b) . While it remains to be determined what role the stalk region plays in the conformation of the peptide-bound active GCGR structure, it is clear that the observed orientation of the ECD in the mAb1-bound full-length GCGR crystal structure is not compatible with the class B GPCR two-state peptide-binding model where the C-terminal region of the peptide ligand targets the ECD as observed in hormone-bound ECD crystal structures of class B GPCRs, and the N-terminal region of the peptide ligand targets the TMD binding pocket 2, 5, 16 (Extended Data Fig. 4c) . A change in the relative orientation between the ECD and TMD is therefore required to enable peptide ligand binding, raising the possibility that the stalk region that connects the ECD and TMD plays a specific role in GCGR activation. Consistent with this hypothesis, mutagenesis of the stalk region has been shown to affect peptide ligand binding 8 , establishing its importance either through direct interactions with the peptide or through modulation of the stalk conformation, which in turn could influence the accessible conformation of the ECD relative to the TMD. Compared to the α -helical conformation of the stalk region observed in the GCGR TMD structure 8 , the extended β -strand conformation in the full-length GCGR structure allows more flexibility for the stalk to adjust its conformation to influence peptide ligand binding. Previous hydrogen-deuterium exchange (HDX) studies comparing small-molecule allosteric antagonist-and peptide antagonist-bound GCGRs revealed differential HDX behaviour for the stalk region, indicating that this region is structurally dynamic upon binding of different ligands 7 , further supporting the important role of the stalk in peptide ligand binding.
The antibodies mAb1 and mAb23 have been studied for their effects on GCGR activation 6 . The investigations showed that mAb1 behaves as an antagonist by blocking ligand access through direct interactions with the residues in the ECD required for glucagon binding, while mAb23 not only blocks glucagon binding but also reduces basal receptor activity, acting as an inverse agonist. To study the structural basis for the differential effects of mAb1 and mAb23 on receptor signalling, we carried out HDX experiments with NNC0640-stabilized GCGR in complex with mAb1 or mAb23 (Extended Data Fig. 5 and Extended Data Fig. 6 ). The results comparing the antibody-free GCGR and the GCGR-mAb1 complex demonstrate protection to deuterium exchange in two regions within the ECD, namely the N-terminal part of α A helix (residues L32-L38) and the β 4-L5 region (residues K98-Q105), both of which exhibited increased protection in the mAb1-bound GCGR (Extended Data Fig. 5b, c) . This aligns well with the GCGR-NNC0640-mAb1 complex structure in which both the α A helix and L5 of the ECD interact with mAb1. For the mAb23-bound receptor, the HDX results showed protection in the same regions within α A helix and β 4-L5 as observed for the GCGR-mAb1 complex (Extended Data Fig. 5e, f) , indicating similar binding modes of the GCGR ECD to mAb1 and mAb23. Additionally, the stalk region (residues I128-M137) displayed protection in the GCGR-mAb23 complex, but not in the mAb1-bound GCGR (Extended Data Fig. 5d, g ), suggesting that binding of mAb23 most likely stabilizes the conformation of the stalk, which may lock GCGR in an inactive state and inhibit the basal activity of the receptor. Taken together, the full-length GCGR crystal structure combined with the HDX studies suggests that the stalk region is involved in regulating or responding to ligand binding through conformational changes and thereby may play a critical role in modulating receptor activity.
Inactive state stabilized by the stalk and ECL1
In class B GPCRs, ECL1 is highly variable in sequence and length, providing potential specificity for recognition of their cognate ligands. GCGR and some other class B GPCRs, including GLP-1R, parathyroid hormone receptor and gastric inhibitory polypeptide receptor, contain a long ECL1 with 11-26 residues, as compared with 4-6 residues in other class B and most class A GPCRs. Previous studies reported that the ECL1 of GCGR might participate in binding to its endogenous ligand glucagon and regulating receptor activity 17, 18 . However, the regulation mechanism of GCGR activation by its ECL1 remained unclear, in part owing to the absence of the conformational information of ECL1 in the previously solved crystal structures of the GCGR TMD. In the full-length GCGR crystal structure, ECL1 (residues R201-S217) of the receptor forms a β -hairpin with G207-D209 on the tip of the turn, which is adjacent to the extracellular tip of helix I ( Fig. 3b and Extended Data Fig. 3b ). The observed conformation of ECL1 is supported by the previous study using a cysteine accessibility method that suggested that this extracellular loop of GCGR is in an extended conformation, probably a β -sheet 18 . Furthermore, it was proposed that ECL1 forms a compact structure or interacts with other parts of the receptor 18 . This agrees with the full-length GCGR crystal structure in which ECL1 of the receptor runs in parallel with the stalk and its backbone from L210-T214 forms hydrogen bonds with the main chain of the residues E126-V130 on the stalk, forming a compact β -sheet structure (Fig. 3b) . Additionally, the main chain nitrogen of E126 hydrogen-bonds with the side chain of T214, and another hydrogen bond is formed between the side chains of E127 and S211.
In the full-length GCGR structure, the β -sheet formed by the stalk and ECL1 stacks on top of helices I, II and III, and partially caps the orthosteric ligand-binding pocket within the TMD (Fig. 3b) . Structural superimposition analysis between the full-length GCGR crystal structure and the previous GCGR-glucagon complex model 7 reveals that glucagon forms spatial clashes with the stalk, suggesting that the conformation of the stalk observed in the full-length GCGR crystal structure may potentially block peptide ligand binding (Fig. 3c) . The strong interactions between the stalk and ECL1 restrain movement of the stalk, and thus may inhibit receptor activation. To further validate the observed conformation of the stalk and ECL1 and their effects on receptor activation, we performed disulfide crosslinking studies to lock the interaction between these two regions (Fig. 4) . The results showed that a GCGR mutant (V130C in the stalk and L210C in ECL1) significantly diminished its binding ability to glucagon, while adding 1 mM dithiothreitol (DTT) rescued glucagon binding by about 50% compared to the wild-type receptor (Fig. 4b) . By contrast, the single mutants V130C and L210C retained 50-100% of glucagon binding of the receptor, and DTT had little effect on the binding potency of these single-site mutants and the wild-type GCGR ( Fig. 4c-e) . These data suggest the formation of a disulfide bond between V130C and L210C, and indicate that locking the stalk and ECL1 together inhibits glucagon binding. To further confirm the roles of these two regions in receptor signalling, we measured glucagon-induced cAMP accumulation for The ECD, stalk and TMD in the full-length GCGR structure are coloured orange, green and blue, respectively. The stalk and TMD in the GCGR TMD structure (PDB ID: 4L6R) are yellow and grey, respectively. b, Interactions between the stalk and ECL1 in the full-length GCGR structure. The stalk (residues G125-K136), ECL1 (residues R201-S217) and TMD (residues M137-T200 and D218-W418) are coloured green, magenta and blue, respectively. The residues involved in stalk-ECL1 interactions are displayed as sticks. Hydrogen bonds are shown as blue dashed lines. c, Structural superimposition between the full-length GCGR crystal structure and the model of the GCGR-glucagon complex 7 . The ECD, stalk, ECL1 and TMD in the full-length GCGR crystal structure are coloured orange, green, magenta and blue, respectively. The receptor in the GCGR-glucagon model is grey and glucagon is cyan. both wild-type GCGR and its mutants V130C/L210C, V130C and L210C (Extended Data Fig. 2c, d ). The data show that the engineered disulfide bond between V130C and L210C decreased the glucagon potency for GCGR by 10-100-fold compared to the wild-type receptor and the two single-site mutants. Adding 1 mM DTT rescued the glucagon potency of the mutant V130C/L210C to a similar level as the native potency of the single-site mutant V130C. Unlike the double-cysteine mutant, cAMP accumulation for the wild-type receptor and the single-site mutants was not affected by DTT. In the full-length GCGR crystal structure, residues V130 on the stalk and L210 on ECL1 are in close contact with their main chains forming hydrogen bonds to stabilize the interaction between the stalk and ECL1 (Figs 3b and 4a) . Thus, the disulfide crosslinking studies support the observed conformation of the stalk and ECL1, and indicate that the interaction between the stalk and ECL1 plays an important role in modulating peptide ligand binding and receptor activation.
Conformational changes of the stalk and ECL1, probably the dissociation of these two fragments followed by a change in the relative orientation between the ECD and TMD, are required for GCGR binding to its cognate peptide ligand and activation of the receptor. This aligns with the HDX studies demonstrating that regions of both the stalk and ECL1 displayed increased protection in the peptide-bound GCGR compared with the small-molecule antagonist-bound receptor, suggesting that these two regions adopt variable conformations when different ligands bind to the receptor 7 . A previous cysteine accessibility study found that accessibility of the mutant L198 2.71b C on the extracellular side of helix II was low in the absence of ligand but increased upon glucagon binding 18 , indicating that the residue L198 2.71b , which was reported to be involved in glucagon binding 8 , might be buried by other residues of the receptor in the inactive state and exposed to an aqueous environment in active conformation. In the inactive full-length GCGR structure, L198
2.71b is directly beneath ECL1 and the stalk, which may provide a 'shelter' for this residue in the inactive state and change conformation to facilitate peptide ligand binding in the active state. Thus, the stalk and ECL1 are likely to act as modulators between the ECD and TMD, and play critical roles in regulating the signal transduction of the GCGR.
The importance of the interface between the ECD, linker domain and TMD for stabilizing the inactive state of receptor was also reported in the recently published structure of the smoothened receptor (SMO) 19 . It was proposed that the receptor activity of SMO is controlled by ligand-regulated interactions between its ECD and TMD
19
. Structures of GCGR and SMO, both of which contain large ECDs, provide essential insights into the signal transduction of non-class-A GPCRs.
Conformational states of GCGR
To investigate the conformational flexibility of apo GCGR, we performed three independent 1-μ s molecular dynamics simulations on the full-length GCGR crystal structure with mAb1 and NNC0640 removed. The molecular dynamics simulations revealed significant motions of the ECD during the first 300 ns and relatively stable conformations of this region in the latter part of the simulations (Extended Data Fig. 7a ). Although the ECD ended up with different conformations in the three simulations, in each simulation it underwent similar movements with the ECD shifting towards the TMD and approaching the stalk and ECL1 (Extended Data Fig. 7b-d) . Throughout the duration of the three simulations, the stalk maintained its extended conformation and close contact with ECL1, and ECL1 retained the β -sheet conformation in most of the snapshots (Extended Data Fig. 7e ). These simulations suggest that the basic features associated with the inactive state remain intact even in the absence of mAb1. Specifically, the ECD and stalk retain orientations that preclude binding of the glucagon peptide in a signalling competent manner.
In the molecular dynamics simulations, extensive interactions between the ECD and the stalk/ECL1 region were observed (Extended Data Fig. 8a) . Comparison between the predicted apo GCGR conformation and the previous model of the GCGR-glucagon complex 7 , as well as the crystal structure of the GCGR-NNC0640-mAb1 complex, revealed a common binding interface on the ECD of GCGR shared by the stalk/ECL1, glucagon and mAb1 (Extended Data Fig. 8b-d) , further suggesting that the stalk and ECL1 may play critical roles in regulating peptide agonist binding and receptor activation. To confirm the existence of molecular contact between the ECD and stalk/ECL1 and its effect on receptor activity, we performed disulfide crosslinking studies to lock these two regions together. The results showed that the glucagon-binding ability of the receptor was reduced by the single-site mutations Q113C on the ECD and D209C on ECL1 to about 20% and 60%, respectively, while adding 1 mM DTT had little effect on the binding potency of these two single-site mutants. By contrast, the double cysteine mutant Q113C/D209C lost its binding ability to glucagon, which was partially rescued (about 20% compared to the wild-type receptor) by addition of 1 mM DTT (Extended Data Fig. 2e-g ). Since the recovery of 20% of the glucagon-binding ability corresponds to the effect of one of the single-site mutations, Q113C, these data support the molecular contact between the ECD and ECL1 as observed in the molecular dynamics simulations, and suggest that the interaction between these regions may play important roles in constraining the conformation of the apo receptor in an inactive state. Previous molecular dynamics simulations and disulfide crosslinking studies indicated that the ECD of apo GCGR interacts with ECL1 and can be crosslinked to ECL3 (ref. 7) , whereas chimaera studies suggested that the ECD of GCGR stabilizes the receptor in an inactive state through interactions with ECL3 (ref. 6) . These data combined with our studies suggest the existence of a dynamical interface between the ECD and TMD of GCGR.
Based on the full-length GCGR crystal structure, the results of molecular dynamics simulations and disulfide cross linking studies, together with the previous glucagon-GCGR binding studies, we postulate a hypothetical structural model of how glucagon and mAb1 are recognized by the apo GCGR (Fig. 5) . In the apo state, the stalk and ECL1 may form extensive hydrophobic and polar interactions with the ECD, constraining the conformation of the apo receptor in an inactive state. With the competition of mAb1, the ECD would most likely dissociate from the stalk and ECL1, releasing its binding interface for interactions with mAb1. The antibody then interacts with the ECD to prevent the binding between the C terminus of glucagon and the receptor, while the stalk and ECL1 form a compact β -sheet conformation to block the entrance of the N terminus of glucagon to the binding pocket within the TMD. A hypothetical model of glucagon binding to GCGR requires the dissociation of the ECD and stalk/ECL1 to initiate the recognition between the ECD and the C terminus of glucagon. Binding of the peptide agonist may trigger a conformational rearrangement of the ECD relative to the TMD either driven by or resulting in a conformational change of the stalk region, possibly including its dissociation with ECL1 and/or a change in secondary structure. The ECD bound to glucagon can then assume a position amenable for direct interactions between the N terminus of glucagon and the TMD, resulting in activation of the receptor. Further details of the interactions between GCGR and the peptide ligand, such as the structure of GCGR-glucagon complex, are required to fully understand the activation mechanism of this receptor.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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MethOds
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Cloning and insect cell expression of full-length GCGR. The codon-optimized human GCGR gene (Genewiz) was cloned into a modified pFastBac1 vector with hemagglutinin (HA) signal sequence at the N terminus and a PreScission protease site followed by a 10× His tag and a Flag tag at the C terminus. To facilitate crystallization, T4L was inserted into the second intracellular loop (ICL2) of GCGR between A256 and E260. To further improve thermostability, 45 residues (H433-F477) were truncated at the C terminus. Our ligand-binding assay showed that protein engineering had little effect on the binding affinity of GCGR to NNC0640 (Extended Data Fig. 2a) . The optimized GCGR construct was expressed in Spodoptera frugiperda (Sf9) insect cells (obtained from Invitrogen) using the Bacto-Bac Baculovirus Expression System (Invitrogen). Cells were infected at a density of 2 × 10 6 cells per ml with high-titre viral stock at MOI (multiplicity of infection) of 5.0. Cells were collected 48 h after infection and stored at − 80 °C until use. Purification of GCGR-NNC0640-mAb1 complex. The cells expressing the GCGR-T4L protein were lysed in a buffer containing 10 mM HEPES, pH 7.5, 20 mM KCl, 10 mM MgCl 2 and EDTA-free protease inhibitor cocktail tablets (Roche), then prepared with three washes of high salt buffer containing 10 mM HEPES, pH 7.5, 1 M NaCl, 20 mM KCl and 10 mM MgCl 2 . Purified membranes were resuspended in 10 ml lysis buffer with 40% glycerol and stored at − 80 °C.
Purified membranes were thawed in 30 ml buffer containing 10 mM HEPES, pH 7.5, 20 mM KCl, 10 mM MgCl 2 , 13% glycerol, 200 μ M NNC0640 and EDTAfree protease inhibitor cocktail (Roche) at 4 °C for 1 h. The GCGR protein was extracted by adding 10 ml solubilization buffer containing 4% (w/v) n-dodecyl-β -d-maltopyranoside (DDM, Anatrace) and 0.8% (w/v) cholesteryl hemisuccinate (CHS, Sigma) at 4 °C for 3 h. The supernatant was isolated by ultracentrifugation at 160,000g for 30 min, and the final concentrations of NaCl and DDM were adjusted to 0.8 M and 0.5% by adding 40 ml buffer containing 50 mM HEPES, pH 7.5 and 1.6 M NaCl. The supernatant was incubated with TALON resin (Clontech) overnight at 4 °C.
The TALON resin was washed with 25 column volumes of wash buffer 1 containing 25 mM HEPES, pH 7.5, 500 mM NaCl, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 10% glycerol, 30 μ M NNC0640 and 30 mM imidazole, and then followed by incubation with mAb1 at a molar ratio of 1:1.2 in 2 ml of wash buffer 2 containing 25 mM HEPES, pH 7.5, 150 mM NaCl, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 10% glycerol, 30 μ M NNC0640 and 10 mM imidazole at 4 °C for 2 h. The unbound mAb1 was removed by washing the resin with 13 column volumes of wash buffer 2. The GCGR-NNC0640-mAb1 complex was eluted with 5 column volumes of 25 mM HEPES, pH 7.5, 150 mM NaCl, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 10% glycerol, 30 μ M NNC0640 and 300 mM imidazole. The PD MiniTrap G-25 column (GE Healthcare) was used to remove imidazole. The sample was treated overnight with His-tagged PreScission protease (custom-made) to remove the C-terminal His-and Flag-tags, and His-tagged PNGase F (custom-made) was also added to deglycosylate the receptor. The Ni-NTA resin (Qiagen) was incubated with the sample at 4 °C for 1 h to remove the cleaved His-tag and PreScission protease. The purified GCGR-NNC0640-mAb1 complex was concentrated to 20-30 mg ml −1 with a 100 kDa molecular weight cut-off concentrator (Millipore). Crystallization in lipidic cubic phase and data collection. Crystallization was performed using the lipidic cubic phase (LCP) method 21 . The GCGR-NNC0640-mAb1 protein (20-30 mg ml −1 ) was mixed with lipid (monoolein/cholesterol 10:1 by mass) at weight ratio of 2:3 using a syringe mixer. The LCP mixture was dispensed onto 96-well glass sandwich plates (Shanghai FAstal BioTech) in 35 nl drop and overlaid with 800 nl precipitant solution using a Mosquito LCP robot (TTP Labtech). Protein reconstitution in LCP and crystallization trials were performed at room temperature (19-22 °C). Plates were incubated and imaged at 20 °C using an automated incubator/imager (RockImager, Formulatrix). Crystals grew in 100 mM HEPES, pH 7.0, 200-300 mM potassium phosphate monobasic, 20-30% (v/v) PEG 500DME and 10-60 mM Gly-Gly-Gly, and reached to a full size of 60-100 μ m after 15 days. Crystals were harvested using 75-100 μ m MiTeGen micromounts (M2-L19-50/150, MiTeGen) and immediately flash-frozen in liquid nitrogen. Data collection was performed at the SPring-8 beam line 41XU, Hyogo, Japan, using a Pilatus3 6M detector (X-ray wavelength 1.0000 Å). The crystals were exposed with a 10 μ m × 8 μ m mini-beam for 0.2 s and 0.2° oscillation per frame. Owing to radiation damage, data collection was limited to 10-15° per crystal. Diffraction data from 26 crystals were integrated and scaled using XDS 22 . The crystals for X-ray free-electron laser (XFEL) data collection were obtained 23 by injecting 6-8 μ l of LCP sample as a continuous column into a syringe filled with 80 μ l precipitant solution comprised of 100 mM HEPES, pH 7.0, 300 mM potassium phosphate monobasic, 25% (v/v) PEG 500DME and 100 mM Gly-GlyGly. The syringe was sealed up and incubated at 20 °C. The excess precipitant was removed after the crystals appeared. The 7.9 MAG was added to absorb the residual precipitant solution and avoid the problem of lipid freezing upon injecting LCP in vacuum 24 . LCP-SFX experiments were carried out at the Coherent X-ray Imaging (CXI) instrument 25 at the Linac Coherent Light Source (LCLS) in the SLAC National Accelerator Laboratory. X-ray pulses of 40 fs duration at a wavelength of 1.3 Å (9.5 keV) were attenuated to around 6% (9 × 10 10 photons per pulse) and focused to approximately 1.5 μ m diameter at the interaction point using Kirkpatrick-Baez mirrors 26 . GCGR-NNC0640-mAb1 complex crystals in LCP were injected across the XFEL beam using an LCP injector 24 with a 50 μ m diameter nozzle at a flow rate of approximately 0.2 μ l min
. Diffraction patterns were collected at 120 Hz using the Cornell-SLAC Pixel Array Detector (CSPAD). Over 1 million data frames were collected corresponding to around 2.3 h of data acquisition time. Of these frames, approximately 6.5% contained potential crystal hits as identified using Cheetah 27 (more than 15 Bragg peaks of minimum 2 pixels in size and a signal to noise ratio better than 7 after local background subtraction). Of the 91,626 potential crystal hits, 57,573 diffraction patterns could be autoindexed by CrystFEL 28 (indexing rate of 63%) using a combination of MOSFLM 29 , asdf 28 and DirAx
30
.
Reflections from different crystals in random orientations were merged using a Monte Carlo integration of each reflection by CrystFEL 28 . The data used for the structure refinement were truncated at 3.0 Å based on the criteria of data correlation coefficient (CC* ) cut-off of 0.5. The statistics of the final data used in structure refinement are shown in Extended Data Table 1 . Structure determination. Both the synchrotron data and XFEL data were initially merged according to the apparent Laue group of mmm. Molecular replacement searches were performed in all possible space groups of mmm, but no satisfying structure solution was found. The data were then reprocessed with the Laue group of 2/m, and the axis length of 245.3 Å was selected as the 2 1 screw axis based on systematic absences of the merged synchrotron data, with a β angle very close to 90° (90.01°).
Both the large crystals for synchrotron data collection and the small crystals for XFEL data collection appeared to be pseudo-merohedrally twinned based on the L-test analysis by Phenix Xtriage 31 with the multivariate score of 7.8. Despite the challenge of twinned data, the GCGR-NNC0640-mAb1 complex structure was solved by molecular replacement (MR) implemented in Phaser 32 using the models of the GCGR TMD, mAb1-bound ECD of GCGR, and T4L (PDB IDs: 4L6R, 4LF3 and 2RH1, respectively). Two molecules of GCGR TMD, two molecules of mAb1-bound GCGR ECD and one molecule of T4L were found sequentially by MR search. The second T4L was partially resolved based on the electron density.
The structure was initially solved and refined against the synchrotron data without using a twin law to an R free of approximately 33% with REFMAC 33 and BUSTER 34 . The model maps from the data were of sufficient quality to interpret the overall structure of the GCGR-NNC0640-mAb1 complex, and both the stalk and ECL1 were built based on the electron map. The model then underwent iterated cycles of manual building into | 2F o | − | F c | maps with Coot 35 and refinement with REFMAC 33 , where rigid body, individual positions and TLS refinements were used along with NCS restraints and a twin law (h, -k, -l). The final structure refined by synchrotron data was then used as a search model for the XFEL data, and the XFEL structure was refined in a similar strategy as described above. Both structures have been carefully refined and the ramachandran plot analysis indicates that 100% of the residues are in favourable or allowed regions (no outliers).
The structures of the GCGR-NNC0640-mAb1 complex were determined to 3.0 and 3.2 Å resolution using the XFEL data and synchrotron data, respectively (Extended Data Table 1 ). The two structures are similar with C α r.m.s.d. of 0.6 Å. Structure analysis and discussion are based on the structure solved using the XFEL data at higher resolution. Expression and purification of the Fab fragment of mAb1. The genes of light chain and heavy chain of mAb1 Fab fragment were synthesized with CD33 signal peptide and cloned into the vector pJSV002 for mammalian cell expression. The plasmids were then transfected into HEK293-6E cells (obtained from Invitrogen) at a density of 1.0 × 10 6 cells per ml with DNA molar ratio of 1:1. Cells were routinely tested for mycoplasma contamination. The transfection was performed following Invitrogen's Freestyle_293 expression manual. The cell culture supernatant was filtered 120 h after transfection and applied to a protein G affinity column (GE Healthcare) that was pre-equilibrated in phosphate-buffered saline (PBS). The bound Fab was eluted with 100 mM glycine-HCl, pH 2.8. Fractions were collected and neutralized immediately with 1/20 volume of 2 M Tris-HCl, pH 9.0. The pooled fraction was then diluted into 20 mM Na-acetate, pH 5.5 and applied to a SP HP column (GE Healthcare). The bound Fab was eluted with a 100-300 mM linear gradient of NaCl in 20 mM Na-acetate, pH 5.5 and buffer-exchanged to PBS on a G25 desalting column (GE Healthcare). Purified protein was sterilized by filtration through a 0.2 mm filter unit (Sartorius). The purity of the protein sample was analysed by SDS-PAGE and size-exclusion chromatography. The Fab identity was confirmed by mass spectrometry. Construction of GCGR mutants and cell transfection. The complementary DNA (cDNA) encoding the human GCGR was originally obtained from GeneCopoeia
